Table 2.
FY99 | FY01 | FY03 | FY05 | FY07 | FY09 | |
---|---|---|---|---|---|---|
SSRI/SNRI | ||||||
Women | 56.4 % | 62.3 % | 68.4 % | 67.5 % | 66.1 % | 65.7 % |
Men | 49.2 % | 53.3 % | 58.0 % | 58.9 % | 58.2 % | 58.3 % |
OR (95 % CI) | 1.34 | 1.45 | 1.57 | 1.45 | 1.40 | 1.37 |
(1.28, 1.39) | (1.40, 1.51) | (1.51, 1.62) | (1.41, 1.49) | (1.36, 1.44) | (1.34, 1.40) | |
Benzodiazepines | ||||||
Women | 33.4 % | 36.3 % | 37.3 % | 37.5 % | 39.1 % | 38.3 % |
Men | 36.7 % | 35.2 % | 33.4 % | 31.7 % | 31.3 % | 29.8 % |
OR (95 % CI) | 0.86 | 1.05 | 1.18 | 1.30 | 1.41 | 1.47 |
(0.83, 0.90) | (1.01, 1.09) | (1.14, 1.23) | (1.26, 1.33) | (1.38, 1.45) | (1.43, 1.50) | |
Atypical antipsychotics | ||||||
Women | 14.6 % | 21.6 % | 27.6 % | 29.0 % | 26.6 % | 26.3 % |
Men | 14.1 % | 20.1 % | 25.1 % | 25.6 % | 22.5 % | 21.3 % |
OR (95 % CI) | 1.05 | 1.09 | 1.14 | 1.19 | 1.25 | 1.31 |
(0.99, 1.11) | (1.05, 1.15) | (1.10, 1.18) | (1.15, 1.22) | (1.22, 1.29) | (1.28, 1.35) | |
Zolpidem | ||||||
Women | 3.8 % | 5.7 % | 5.6 % | 5.5 % | 6.1 % | 16.9 % |
Men | 3.8 % | 4.9 % | 4.3 % | 3.9 % | 4.2 % | 12.4 % |
OR (95 % CI) | 1.02 | 1.18 | 1.33 | 1.44 | 1.48 | 1.43 |
(0.92, 1.13) | (1.09, 1.28) | (1.24, 1.43) | (1.35, 1.53) | (1.40, 1.56) | (1.39,1.48) | |
Prazosin | ||||||
Women | 0.2 % | 0.7 % | 1.9 % | 3.5 % | 5.0 % | 7.1 % |
Men | 1.5 % | 1.6 % | 2.6 % | 4.8 % | 6.4 % | 9.3 % |
OR (95 % CI) | 0.14 | 0.41 | 0.73 | 0.73 | 0.76 | 0.75 |
(0.09, 0.21) | (0.32, 0.51) | (0.64, 0.82) | (0.67, 0.79) | (0.72, 0.80) | (0.72, 0.78) |